The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index, and 2 are not checked yet; 80 of the 107 sources its claims cite were checked for support.
Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies
Open accessAbstract
KRAS is one of the most frequently mutated oncogenes in human cancer and has long been considered an “undruggable” therapeutic target because of its high affinity for guanine nucleotides and limited druggable binding pockets. Recent advances in structural biology and molecular pharmacology have transformed this paradigm, leading to the successful development of KRAS G12C inhibitors such as sotorasib and adagrasib. These agents established proof-of-concept for direct KRAS inhibition and marked an important advance in precision oncology. However, intrinsic and acquired resistance mechanisms, adaptive signaling reactivation, and tumor heterogeneity continue to limit the durability of clinical responses. Therapeutic development has rapidly expanded beyond KRAS G12C toward broader strategies including KRAS G12D inhibitors, pan-RAS and RAS(ON) inhibitors, degraders, and biomarker-guided combination approaches. In parallel, circulating tumor DNA (ctDNA) and other biomarker-driven strategies are increasingly enabling dynamic monitoring of treatment response, minimal residual disease, and resistance evolution. In this review, we summarize the molecular biology and conformational regulation of KRAS signaling, recent advances in allele-specific and pan-RAS therapeutic strategies, mechanisms of resistance, and emerging precision oncology frameworks for KRAS-mutant cancers.
Verified 2026-10-10 · 2 references not checked yet
Overview
CoChat Summary
TL;DR
This narrative review synthesizes the shift in KRAS-targeted oncology from G12C OFF-state inhibitors toward G12D, RAS(ON)/pan-RAS, degrader, and biomarker-guided strategies. It argues that KRAS allele, nucleotide/conformational state, tumor lineage, resistance mechanism, and ctDNA dynamics should guide therapy, while noting many non-G12C and pan-RAS approaches remain investigational.
Key findings
- KRAS G12C inhibitors established proof-of-concept but show lineage-dependent efficacy: in CodeBreaK 100, sotorasib produced an ORR of approximately 41%, median PFS of 6.3 months, and median OS of 12.5 months; in CodeBreaK 200, sotorasib improved PFS versus docetaxel (5.6 vs. 4.5 months; HR 0.66) and ORR (28.1% vs. 13.2%), but not OS (10.6 vs. 11.3 months; HR 1.01).
- EGFR blockade is needed in KRAS G12C-mutant colorectal cancer because of rapid EGFR-mediated adaptive reactivation: KRYSTAL-1 reported adagrasib plus cetuximab ORR 34.0%, median PFS 6.9 months, and median OS 15.9 months; CodeBreaK 300 reported sotorasib plus panitumumab median PFS 5.6 vs. 2.2 months and ORR 26% vs. 0%.
- Beyond G12C, KRAS G12D lacks a covalent cysteine handle and requires non-covalent or active-state strategies; MRTX1133 provided preclinical proof-of-concept but its clinical trial was terminated for formulation challenges, while zoldonrasib and other G12D agents remain in early evaluation.
- RAS(ON)/pan-RAS inhibition may broaden allele coverage: in the phase III RASolute 302 trial in previously treated metastatic PDAC, daraxonrasib improved median OS (13.2 vs. 6.7 months) and median PFS (7.2 vs. 3.6 months) versus chemotherapy, though wild-type RAS inhibition and therapeutic window remain concerns.
Methods
- Narrative review with a scoping approach, not a systematic review or meta-analysis; literature was identified from PubMed, ClinicalTrials.gov, regulatory documents, major oncology conference abstracts, and publicly available company disclosures up to May 2026.
- Evidence was categorized by maturity: Level 1, approved therapy or randomized phase III; Level 2, peer-reviewed phase I/II; Level 3, registry data, conference abstracts, or company disclosures without mature peer-reviewed publication; Level 4, preclinical; Level 5, conceptual or hypothesis-generating.
- Priority was given to peer-reviewed original studies, randomized clinical trials, regulatory documents, and clinical trial registry records; conference abstracts and company disclosures were included only when peer-reviewed data were unavailable and are indicated as preliminary or non-peer-reviewed.
Limitations
- Stated: the article is a narrative review with a scoping approach and was not designed as a systematic review or meta-analysis; conclusions were calibrated according to an evidence hierarchy, and non-peer-reviewed sources are flagged when used.
- Stated: biomarker-guided treatment utility remains uneven—KRAS allele status is clinically actionable, but ctDNA-guided treatment switching, MRD-based escalation, and perioperative adaptation remain investigational; co-mutations, tumor lineage, and serial ctDNA dynamics are variably validated.
- Evident: the review relies on secondary literature and rapidly evolving clinical data, and many discussed agents are preclinical, early-stage, or discontinued (e.g., MRTX1133, JDQ443), limiting the durability and generalizability of conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
40 Valid · 8 Not valid · 8 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“KRAS was long considered an “undruggable” target because of its high affinity for GTP/GDP and the lack of obvious druggable binding pockets [2,3].”
§ Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies > 1. Introduction
What the sources say
- Supportedcites [2] Cox, 2014, Drugging the undruggable RAS: Mission possible?, Nat. Rev. Drug Discov. source
In “Direct inhibitors of Ras – druggable after all?”, the review says direct targeting had been thought very challenging, if not impossible, because K-Ras appeared to lack deep hydrophobic pockets for tight small-molecule binding. The “Mutant-specific inhibitors” section says nucleotide-site approaches had been disregarded because GTP and GDP bind K-Ras with picomolar affinity and are abundant in cells. These passages support both reasons given in the claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [3] Kano, 2016, New structural and functional insight into the regulation of Ras, Semin. Cell Dev. Biol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This paradigm changed following the discovery of the switch-II pocket, which enabled development of covalent KRAS G12C inhibitors such as sotorasib and adagrasib [5,6,7].”
§ Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies > 1. Introduction
What the sources say
- Partly supportedcites [5] Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature sourceExperimental — accuracy not yet measured
The paper’s Abstract describes identifying the switch-II pocket and using it to develop early irreversible, mutant-specific KRAS G12C inhibitors. It presents those findings as a starting point for future drug discovery, but our copy does not identify sotorasib or adagrasib or establish a specific link to their development. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [6] Patricelli, 2016, Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State, Cancer Discov. source
- Partly supportedcites [7] Janes, 2018, Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor, Cell sourceExperimental — accuracy not yet measured
The Introduction describes the discovered switch-II pocket, and the Summary and Results describe development of the covalent KRAS G12C inhibitor ARS-1620. Our copy does not mention sotorasib or adagrasib, so it does not support those specific examples. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clinical efficacy remains limited by intrinsic and acquired resistance, adaptive pathway reactivation, and tumor heterogeneity.”
§ Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies > 1. Introduction
What the sources say
- Partly supportedcites [26] Ryan, 2020, Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition, Clin. Cancer Res. sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports adaptive pathway reactivation and heterogeneous RTK responses across KRAS G12C cancer models. The Discussion (page unavailable) reports that not all patients responded to an early KRAS G12C inhibitor trial, but treats adaptive feedback as a likely clinical resistance mechanism. It does not establish that both intrinsic and acquired resistance, or tumor heterogeneity, are demonstrated causes of limited clinical efficacy. (LLM, conf=0.86)
- Partly supportedcites [27] Amodio, 2020, EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer, Cancer Discov. sourceExperimental — accuracy not yet measured
The Introduction (pp. 3–4) reports limited clinical response to KRAS G12C inhibitors in colorectal cancer and identifies adaptive EGFR reactivation as a restriction on efficacy. The Discussion (p. 7) describes intrinsic signaling differences between colorectal and lung cancers. The paper does not establish acquired resistance to KRAS G12C inhibitors or tumor heterogeneity as causes of limited clinical efficacy. (LLM, conf=0.86)
- Partly supportedcites [35] Awad, 2021, Acquired Resistance to KRASG12C Inhibition in Cancer, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) describes acquired resistance to adagrasib, including multiple concurrent mechanisms and alterations that activate the RTK–RAS pathway. It does not establish intrinsic resistance as a limitation, and says that whether adaptive signaling pathways at baseline explain more modest efficacy in colorectal cancer requires further investigation. (LLM, conf=0.87)
- Partly supportedcites [36] Zhao, 2021, Diverse alterations associated with resistance to KRAS(G12C) inhibition, Nature sourceExperimental — accuracy not yet measured
The paper reports a 30–40% response rate and approximately six-month median progression-free survival in lung cancer, along with heterogeneous treatment-emergent resistance and ERK signaling reactivation (Abstract; page unavailable). It notes baseline KRAS amplification in preclinical models with weaker responses, but does not establish intrinsic resistance as a cause of limited clinical efficacy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These agents established proof-of-concept for direct KRAS inhibition and represented a major proof-of-concept in precision oncology.”
§ Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies > 1. Introduction
What the sources say
- Supportedcites [5] Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature source
The paper’s Abstract reports mutant-specific inhibitors that bind K-Ras(G12C) directly and states that its cellular data provide proof-of-concept for their use in K-Ras(G12C)-driven cancer. This supports the attributed claim as a preclinical proof-of-concept. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [6] Patricelli, 2016, Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State, Cancer Discov. source
- Supportedcites [7] Janes, 2018, Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor, Cell source
The Introduction says ARS-1620 provides proof of concept for covalent, mutant-allele-specific inhibition in KRAS G12C cell lines and in vivo tumor models. The Discussion identifies it as a direct KRAS G12C inhibitor with demonstrated efficacy in tumor models. The paper supports the claim as a preclinical proof of concept, not as proof of clinical efficacy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An important feature of adagrasib is its central nervous system (CNS) activity, including intracranial responses in patients with active brain metastases [30,31].”
§ Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies > 5. Clinical Development of KRAS G12C Inhibition > 5.3. Adagrasib
What the sources say
- Supportedcites [30] Negrao, 2023, Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases, J. Clin. Oncol. source
The Discussion reports intracranial activity and ongoing responses with adagrasib in patients with KRASG12C-mutated NSCLC and untreated CNS metastases. The Methods specify that these metastases were neurologically stable and asymptomatic; within that studied population, untreated metastases support the claim's reference to active brain metastases. (LLM, conf=0.92)
- Supportedcites [31] Bernstein, 2024, Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series, JCO Precis. Oncol. source
The Introduction reports intracranial responses to adagrasib in patients with NSCLC and untreated CNS metastases. The Results also describe a partial intracranial response in a patient with an untreated lesion, supporting the claim of activity in active brain metastases. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims · 24 with their cited sources checked
Create a free account to see all 104 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 9
Citations
Cites
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 1×
“Therapeutic pressure from KRAS inhibition can rapidly reshape tumor clonal architecture [35,36,47,81].”
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 5×
“Ostrem and colleagues demonstrated that covalent small molecules could selectively target KRAS G12C through this pocket, establishing proof-of-concept for direct KRAS inhibition [5].”
InfluentialThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 2×
“By covalently binding the switch-II pocket of GDP-bound KRAS G12C, so-torasib suppresses downstream MAPK signaling [20,21].”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 5×
“Under physiologic conditions, KRAS cycles between inactive GDP-bound and active GTP-bound states through interactions with guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) [4].”
InfluentialSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1×
“In NSCLC, alterations in STK11 , KEAP1 , and TP53 define biologically distinct molecular subsets with different immune phenotypes and treat-ment outcomes [75,76].”
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 3×
“KRAS G12C inhibitors such as sotorasib and adagrasib selectively bind a transient switch-II pocket (S-IIP) adjacent to the switch II region and irreversibly trap KRAS in its inactive GDP-bound state through covalent interaction with Cys12 residue [5–7, 20, 21, 23 , 29].”
Metadata
- Authors
- Kano, Y.
- Affiliations
- Institute of Science Tokyo (JP)
- Corresponding author
- Kano, Yoshihito
- ORCID
- Kano, Yoshihito
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-06-26
- Volume
- 27
- Issue
- 13
- Pages
- 5796
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13362513
- OpenAlex
- W7166532892
- Semantic Scholar
- a262380d1deca3ba924c8550919737a55e65c77f
- Cited by
- 0
- References
- 81
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS, KRAS G12C inhibitors, KRAS G12D inhibitors, pan-RAS inhibitors, sotorasib, adagrasib, resistance mechanisms, tumor heterogeneity, circulating tumor DNA, minimal residual disease, precision oncology, KRAS-mutant cancer
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. https://app.cochat.ai/papers/10.3390/ijms27135796
- The paper
- Kano, Y. (2026). Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.